Report Overview:
Obesity hypoventilation syndrome is defined as alveolar hypoventilation while awake in an obese individual where there is no other cause of the hypoventilation (such as a sedating drug). Ninety percent of people with obesity hypoventilation syndrome (OHS) also have an associated obstructive sleep apnea.The mainstay of treatment in OHS is to provide breathing support, often through the use of continuous positive airway pressure (CPAP) or bilevel.
This report provides a deep insight into the global Obesity Hypoventilation Syndrome Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
Market Value:
The global Obesity Hypoventilation Syndrome Treatment market size was estimated at USD 1280 million in 2023 and is projected to reach USD 2126.09 million by 2032, exhibiting a CAGR of 5.80% during the forecast period.
By Types:
• Oxygen Therapy
• Non-invasive Mechanical Ventilation
• Drug Therapy
By Applications: Hospital
Clinics
Key players include:
• Accord Healthcare Limited
• Avet Pharmaceuticals Inc
• Nostrum Laboratories Inc
• Lannett Co Inc
• Strides Pharma Science Limited
• X Gen Pharmaceuticals Inc
• ResMed
• Including or Excluding key companies relevant to your analysis.
www.statsmarketresearch.com
